Program
QL1203
A development code. Also written as “QL1203 + mFOLFOX6” and “QLC1101+QL1203”.
Its studies are mostly in Colorectal Neoplasms, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 43 open or running | phase 3since Jan 14, 2020 | Jan 14, 2020 | Feb 28, 2028phase 1 · NCT07829588 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 14, 2020First study: phase 3 study in Colorectal NeoplasmsFirst studyNCT04233151 · 590 planned · China
- Jan 16, 2020Phase 1 study in Healthy MalesNCT04234594 · 94 enrolled · China
- Apr 22, 2025Phase 2 study in Solid TumorNCT06949761 · 240 planned
- Sep 9, 2026Phase 1 study in RAS Wild-type Metastatic Colorectal CancerNCT07829588 · 136 planned
Ahead
- Feb 28, 2028Primary completion: phase 1 study in RAS Wild-type Metastatic Colorectal CancerNCT07829588
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07829588RAS Wild-type Metastatic Colorectal Cancer | 1 | Not yet recruiting | Feb 28, 2028 | 136 |
| NCT06949761Solid Tumor | 2 | Not yet recruiting | Sep 2026 | 240 |
| NCT04234594Healthy Males · China | 1 | UNKNOWN | Sep 30, 2020 | 94 |
| NCT04233151Colorectal Neoplasms · China | 3 | Recruiting | Dec 31, 2024 | 590 |
How it is read
Names in the registry
- “QL1203”, 2 entries
- “QL1203 + mFOLFOX6”, 1 entry
- “QLC1101+QL1203”, 1 entry
Codes read as this program: QL1203.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.